JERUSALEM, May 24, 2017 /PRNewswire/ --
Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage
biopharmaceutical company focused on developing drugs based on its
proprietary Accordion Pill™ platform technology, announces that the
United States Patent and Trademark Office has granted the Company
patent No. 9,655,859 titled, "Accordion Pill Comprising Levodopa
for Improved Treatment of Parkinson's Diseases Symptoms." The
patent is scheduled to remain in force until November 2031 and belongs to the Company's IN-11
patent family.
"The approval of this new U.S. patent is a key addition that
extends and strengthens the Company's global intellectual property
portfolio, specifically as it relates to an improved treatment
regimen using Intec's Accordion Pill Carbidopa / Levodopa
(AP-CD/LD), which is currently in a global Phase III clinical trial
in advanced Parkinson's disease patients. The new U.S. patent
joins another U.S. patent family that protects the combination of
Accordion Pill with certain drugs, including the combination of
Carbidopa and Levodopa," noted Giora
Carni, Intec Pharma's Chief Executive Officer. "We continue
to fortify our patent portfolio around our Accordion Pill
technology platform, further protecting and distinguishing it from
would-be competitors and firmly establishing Intec Pharma's leading
patent position for its proprietary oral drug delivery system."
About Intec Pharma Ltd.
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company
focused on developing drugs based on its proprietary Accordion Pill
platform technology. The Company's Accordion Pill is an oral drug
delivery system that is designed to improve the efficacy and safety
of existing drugs and drugs in development by utilizing an
efficient gastric retention and specific release mechanism. The
Company's product pipeline includes four product candidates in
clinical trial stages: Accordion Pill Carbidopa/Levodopa, or
AP-CD/LD, which is being developed for the treatment of Parkinson's
disease symptoms in advanced Parkinson's disease patients;
Accordion Pill Zaleplon, or AP-ZP, which is being developed for the
treatment of insomnia, including sleep induction and the
improvement of sleep maintenance; an Accordion Pill that is being
developed for the prevention and treatment of gastroduodenal and
small bowel Nonsteroidal Anti-Inflammatory Drug (NSAID)-induced
ulcers; and AP-CBD/THC, an Accordion Pill with the two primary
cannabinoids contained in Cannabis sativa, cannabidiol (CBD)
and tetrahydrocannabinol (THC), which is being developed for
various indications including low back neuropathic pain and
fibromyalgia.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements about the
Company's expectations, beliefs and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. These
forward-looking statements are based on assumptions and assessments
made in light of management's experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and the company undertakes no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the company's control.
Important factors that could cause actual results, developments and
business decisions to differ materially from forward-looking
statements are described in the sections titled "Risk Factors" in
the company's filings with the Securities and Exchange Commission,
and include the following: the company's ability to develop and
commercialize its product candidates and obtain additional
financing necessary therefor; the length, cost and uncertain
results of the company's clinical trials; including uncertainty
regarding the Company's ability to enroll the required number of
patients therein; the potential of adverse side effects, other
safety risks, or legal prohibitions on the use of certain products
in certain jurisdictions that could preclude the approval of the
company's drug candidates; the availability of reimbursement from
government authorities and health insurance companies for the
company's products; the impact of product liability lawsuits; and
the influence of extensive and costly government regulation.
Contacts:
Giora Carni
Chief Executive Officer
Intec Pharma
+972-(2)586-4657
Giora@intecpharma.com
Anne Marie Fields
Senior Vice President
LHA
212-838-3777
afields@lhai.com
SOURCE Intec Pharma Ltd.